Performance of a shortened Scale for Assessment of Positive Symptoms for Parkinson's disease psychosis.

作者: Tiffini Voss , Daun Bahr , Jeffrey Cummings , Roger Mills , Bernard Ravina

DOI: 10.1016/J.PARKRELDIS.2012.10.022

关键词:

摘要: Abstract Background Parkinson's disease psychosis is a frequent and serious complication of advanced disease, but few disease-specific outcome measures exist. Methods Using baseline scores from 4 clinical trials, we identified relevant items that assessed to create shortened version the Scale for Assessment Positive Symptoms. We then analyzed validity treatment sensitivity scale. Principal component analyses evaluated underlying structure. Scores were compared across age, gender, trial, cognition, country origin. Sensitivity change was by comparing in global impression improvement score, effect sizes calculated evaluate response. Results Nine selected based on face-validity symptom frequency. analysis yielded 4-factor structure delusions visual, auditory, somatic hallucinations as distinct constructs. Baseline total similar study, region, age group. The clinically meaningful scale, defined 1-unit impression, 2.33 points, size was −0.722. did not significantly differ between those with cognitive impairment without. Conclusions Symptoms retains reliability, change, larger scale while reducing administration time and, more importantly, score variability. an effective measure use trials.

参考文章(10)
Herbert Y Meltzer, Roger Mills, Stephen Revell, Hilde Williams, Ann Johnson, Daun Bahr, Joseph H Friedman, Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis. Neuropsychopharmacology. ,vol. 35, pp. 881- 892 ,(2010) , 10.1038/NPP.2009.176
S Holroyd, Prospective study of hallucinations and delusions in Parkinson's disease Journal of Neurology, Neurosurgery & Psychiatry. ,vol. 70, pp. 734- 738 ,(2001) , 10.1136/JNNP.70.6.734
Hubert H Fernandez, Dag Aarsland, Gilles Fénelon, Joseph H Friedman, Laura Marsh, Alexander I Tröster, Werner Poewe, Olivier Rascol, Cristina Sampaio, Glenn T Stebbins, Christopher G Goetz, None, Scales to assess psychosis in Parkinson's disease: Critique and recommendations Movement Disorders. ,vol. 23, pp. 484- 500 ,(2008) , 10.1002/MDS.21875
Tiffini S. Voss, Alicia F.D. Brocht, Bernard Ravina, Performance of the scale for assessment of positive symptoms in Parkinson's disease psychosis Movement Disorders. ,vol. 25, pp. 124- 125 ,(2010) , 10.1002/MDS.22575
S. A. Factor, P. J. Feustel, J. H. Friedman, C. L. Comella, C. G. Goetz, R. Kurlan, M. Parsa, R. Pfeiffer, the Parkinson Study Group, Longitudinal outcome of Parkinson’s disease patients with psychosis Neurology. ,vol. 60, pp. 1756- 1761 ,(2003) , 10.1212/01.WNL.0000068010.82167.CF
Arif Khan, Robyn M Leventhal, Shirin R Khan, Walter A Brown, None, Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. Journal of Clinical Psychopharmacology. ,vol. 22, pp. 40- 45 ,(2002) , 10.1097/00004714-200202000-00007
Bernard Ravina, Karen Marder, Hubert H. Fernandez, Joseph H. Friedman, William McDonald, Diane Murphy, Dag Aarsland, Debra Babcock, Jefferey Cummings, Jean Endicott, Stewart Factor, Wendy Galpern, Andrew Lees, Laura Marsh, Mark Stacy, Katrina Gwinn-Hardy, Valerie Voon, Christopher Goetz, Diagnostic criteria for psychosis in Parkinson's disease: Report of an NINDS, NIMH work group Movement Disorders. ,vol. 22, pp. 1061- 1068 ,(2007) , 10.1002/MDS.21382
Irving Kirsch, Brett J Deacon, Tania B Huedo-Medina, Alan Scoboria, Thomas J Moore, Blair T Johnson, Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLOS Medicine. ,vol. 5, pp. 0260- 0268 ,(2008) , 10.1371/JOURNAL.PMED.0050045